Kinaset Therapeutics Raises $103M to Advance Inhaled Asthma Drug
Kinaset Therapeutics secured $103 million in a Series A funding round led by ARCH Venture Partners and Takeda Ventures.
The funds will accelerate development of KIN-190, an inhaled kinase inhibitor targeting severe asthma and chronic obstructive pulmonary disease (COPD).
The drug aims to address unmet needs in patients unresponsive to current biologics by inhibiting specific inflammatory pathways directly in the lungs.
Announcement made on January 10, 2026; preclinical data showed promising efficacy in reducing airway inflammation.
Kinaset plans to initiate Phase 1 clinical trials in 2026.